What is the dosage of Valcyclovir (valacyclovir) for treating herpes simplex virus (HSV) flare-ups?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Valacyclovir Dosing for HSV Flare-Ups

For episodic treatment of recurrent genital herpes flare-ups, take valacyclovir 500 mg twice daily for 5 days, starting at the first sign of prodrome or lesions. 1

Standard Episodic Treatment Regimens

The CDC provides multiple effective dosing options for treating HSV recurrences 1:

  • Valacyclovir 500 mg twice daily for 5 days - This is the most convenient valacyclovir regimen 1
  • Alternative acyclovir regimens include 400 mg three times daily, 200 mg five times daily, or 800 mg twice daily for 5 days 1
  • Famciclovir 125 mg twice daily for 5 days is another alternative 1

Treatment should be initiated at the earliest sign of prodrome (tingling, itching, burning) or when lesions first appear to maximize effectiveness. 1, 2

First Episode vs. Recurrent Episodes

If this is a first clinical episode rather than a recurrence, higher dosing is required 1, 3:

  • Valacyclovir 1 gram twice daily for 7-10 days for initial episodes 1, 3
  • Treatment may be extended beyond 10 days if healing is incomplete 1, 3
  • First episodes are typically more severe and require longer treatment duration 1

Special Populations Requiring Modified Dosing

HIV-Infected Patients

  • For episodic treatment: Valacyclovir 1000 mg twice daily for 5 days (higher than immunocompetent dosing) 4
  • For suppressive therapy: 500 mg twice daily for those with CD4+ count ≥100 cells/mm³ 3, 5

Renal Impairment

Dose adjustments are critical to prevent toxicity 2:

  • CrCl 30-49 mL/min: No reduction needed for episodic treatment 2
  • CrCl 10-29 mL/min: 500 mg every 24 hours 2
  • CrCl <10 mL/min: 500 mg every 24 hours 2
  • Hemodialysis patients: Administer dose after dialysis session 2

When to Consider Suppressive Therapy Instead

If you experience frequent recurrences (≥6 episodes per year), daily suppressive therapy may be more appropriate than episodic treatment 1:

  • Valacyclovir 500 mg once daily for patients with ≤9 recurrences per year 1, 5
  • Valacyclovir 1000 mg once daily for patients with ≥10 recurrences per year 1, 5
  • Suppressive therapy reduces recurrence frequency by ≥75% 1, 5

Critical Timing Considerations

  • Episodic therapy is most effective when started within 48 hours of symptom onset 3
  • Patients should keep medication on hand to begin treatment immediately at first symptoms 1
  • The 5-day treatment course should be completed even if symptoms resolve earlier 1

Treatment Failure and Resistance

If lesions persist after completing the full 5-day course 3, 5:

  • Consider HSV resistance to acyclovir/valacyclovir 3, 5
  • All acyclovir-resistant strains are also resistant to valacyclovir 3, 5
  • Switch to IV foscarnet 40 mg/kg every 8 hours until clinical resolution for resistant cases 3, 5

Important Clinical Caveats

  • Valacyclovir provides better bioavailability than acyclovir, allowing less frequent dosing 6, 7, 8
  • The drug does not eliminate latent virus or prevent future recurrences after discontinuation 1
  • Suppressive therapy reduces but does not eliminate asymptomatic viral shedding 1, 5
  • Avoid doses of 8 grams per day in immunocompromised patients due to risk of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome 3, 5, 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Valacyclovir Dosing for HSV-1 Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004

Guideline

Suppressive Therapy for Herpes Simplex Virus

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Valacyclovir. New indication: for genital herpes, simpler administration.

Canadian family physician Medecin de famille canadien, 1999

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.